Einfluss von GLP-1-Analoga auf die Mikronährstoffversorgung

Die Gabe von Glucagon-like Peptid-1-Rezeptoragonisten (GLP-1-RA) stellt einen effizienten Ansatz zur Behandlung der Adipositas dar. Die unter GLP-1-RA beobachtete erhebliche Reduktion der Nahrungsaufnahme wirft Bedenken hinsichtlich einer adäquaten Mikronährstoffversorgung auf. Da bisher hierzu kaum Daten vorliegen, sind Studien erforderlich, um die langfristigen ernährungsbezogenen Auswirkungen von GLP-1-RA systematisch zu untersuchen.

• Literatur

• 1 Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol 2019; 15: 288-298
• 2 Hauner H. et al. Umsetzung der leitliniengerechten Basistherapie der Adipositas in Deutschland. Dtsch Med Wochenschr 2025; 150: 668-674
• 3 Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr 2001; 21: 323-341
• 4 Adams TD, Gress RE, Smith SC. et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357: 753-761
• 5 Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov 2022; 21: 201-223
• 6 Alfaris N, Waldrop S, Johnson V. et al. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. EClinicalMedicine 2024; 75: 102782
• 7 Pi-Sunyer X, Astrup A, Fujioka K. et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373: 11-22
• 8 Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018; 27: 740-756
• 9 Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439
• 10 Bu T, Sun Z, Pan Y. et al. Glucagon-like peptide-1: New regulator in lipid metabolism. Diabetes Metab J 2024; 48: 354-372
• 11 Moiz A, Filion KB, Tsoukas MA. et al. Mechanisms of GLP-1 receptor agonist-induced weight loss: A review of central and peripheral pathways in appetite and energy regulation. Am J Med 2025; 138: 934-940
• 12 Jalleh RJ, Rayner CK, Hausken T. et al. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. Lancet Gastroenterol Hepatol 2024; 9: 957-964
• 13 Gibbons C, Blundell J, Tetens Hoff S. et al. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes Obes Metab 2021; 23: 581-588
• 14 Johnson B, Milstead M, Thomas O. et al. Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study. Front Nutr 2025; 12: 1566498
• 15 Christensen S, Robinson K, Thomas S, Williams DR. Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs. Obes Pillars 2024; 11: 100121
• 16 Reiss AB, Gulkarov S, Lau R. et al. Weight reduction with GLP-1 agonists and paths for discontinuation while maintaining weight loss. Biomolecules 2025; 15: 408
• 17 Wilding JPH, Batterham RL, Calanna S. et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384: 989-1002
• 18 Jastreboff AM, Kaplan LM, Frías JP. et al. Triple-hormone-receptor agonist retatrutide for obesity - A phase 2 trial. N Engl J Med 2023; 389: 514-526
• 19 Berg S, Stickle H, Rose SJ, Nemec EC. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis. Obes Rev 2025; 26: e13929
• 20 Blüher M. Naltrexon/Bupropion in der Adipositastherapie. Adipositas - Ursachen, Folgeerkrankungen, Therapie 2018; 12: 60-67
• 21 Mozaffarian D, Agarwal M, Aggarwal M. et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring) 2025; 33: 1475-1503
• 22 Almandoz JP, Wadden TA, Tewksbury C. et al. Nutritional considerations with antiobesity medications. Obesity (Silver Spring) 2024; 32: 1613-1631
• 23 Gardner CD, Kim S, Bersamin A. et al. Micronutrient quality of weight-loss diets that focus on macronutrients: results from the A TO Z study. Am J Clin Nutr 2010; 92: 304-312
• 24 Zhang W, Chen P, Huo S. et al. Requirements for essential micronutrients during caloric restriction and fasting. Front Nutr 2024; 11: 1363181
• 25 Hart TL, Petersen KS, Kris-Etherton PM. Nutrition recommendations for a healthy pregnancy and lactation in women with overweight and obesity - strategies for weight loss before and after pregnancy. Fertil Steril 2022; 118: 434-446
• 26 Stein J, Stier C, Raab H, Weiner R. Review article: The nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther 2014; 40: 582-609
• 27 Chiang E-P, Smith DE, Selhub J. et al. Inflammation causes tissue-specific depletion of vitamin B6. Arthritis Res Ther 2005; 7: R1254-R1262
• 28 Wiklund CA, Igudesman D, Kuja-Halkola R. et al. Intake and adherence to energy and nutrient recommendations among women and men with binge-type eating disorders and healthy controls. Clin Nutr ESPEN 2022; 48: 186-195
• 29 Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med 2025; 31: 951-962
• 30 He L, Li Q, Yang Y. et al. Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events. Front Pharmacol 2024; 15: 1416985
• 31 White GE, Shu I, Rometo D. et al. Real-world weight-loss effectiveness of glucagon-like peptide-1 agonists among patients with type 2 diabetes: A retrospective cohort study. Obesity (Silver Spring) 2023; 31: 537-544
• 32 Kadouh H, Chedid V, Halawi H. et al. GLP-1 analog modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity. J Clin Endocrinol Metab 2020; 105: 1552-1563
• 33 Heise T, DeVries JH, Urva S. et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care 2023; 46: 998-1004
• 34 Martin CK, Ravussin E, Sanchez-Delgado G. et al. 128-OR: The effect of tirzepatide during weight loss on food intake, appetite, food preference, and food craving in people with obesity. Diabetes 2023; 72
• 35 Friedrichsen M, Breitschaft A, Tadayon S. et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 2021; 23: 754-762